Co-expression of Ubiquitin gene and capsid protein gene enhances the potency of DNA immunization of PCV2 in mice

Virology Journal

Volumn 8, Issue , 2011, Pages

  Fu, Fang ^a   Li, Xuesong ^a,b   Lang, Yuekun ^a   Yang, Yuju ^b   Tong, Guangzhi ^a   Li, Guoxin ^a   Zhou, Yanjun ^a   Li, Xi ^a  

^a INSTITUTE OF PLANT PROTECTION   (China)

^b HARBIN UNIVERSITY   (China)

Author keywords

Cap; DNA immunization; PCV2; Ubiquitin

Indexed keywords

PROTEIN VP1; UBIQUITIN; CAPSID PROTEIN; CYTOKINE; DNA VACCINE; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ANIMAL MODEL; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; TH1 CELL; VACCINATION; VIREMIA; VIRUS CAPSID; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; CELL LINE; CELL PROLIFERATION; CIRCOVIRUS; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; METHODOLOGY; PLASMID; SECRETION;

ANIMALIA; MIRIDAE; MUS; PORCINE CIRCOVIRUS 2;

ANIMALS; ANTIBODIES, VIRAL; CAPSID PROTEINS; CELL LINE; CELL PROLIFERATION; CIRCOVIRUS; CYTOKINES; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; LYMPHOCYTE SUBSETS; MICE; MICE, INBRED BALB C; MICROSCOPY, CONFOCAL; PLASMIDS; UBIQUITIN; VACCINATION; VACCINES, DNA; VIREMIA;

EID: 79957555355     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-264     Document Type: Article

References (38)

1. Characterisation of PCV-2 isolates from Spain, Germany and France. A Mankertz M Domingo JM Folch P LeCann A Jestin J Segalés,, et al. Virus Res 2000 66 65 77 10.1016/S0168-1702(99)00122-7 10653918 (Pubitemid 30069805)
2. Open reading frame 2 of porcine circovirus type 2 encodes a major capsid protein. P Nawagitgul I Morozov SR Bolin PA Harms SD Sorden PS Paul, J Gen Virol 2000 81 2281 87 10950986
3. Kinetics of porcine circovirus type 2 replication. AK Cheung SR Bolin, Arch Virol 2002 147 43 58 10.1007/s705-002-8302-4 11855635 (Pubitemid 34114975)
4. Production, characterization and application of monoclonal antibodies to porcine Circovirus 2. F McNeilly I Mcnair DP Mackie BM Meehan S Kennedy D Moffet,, et al. Arch Virol 2001 146 909 22 10.1007/s007050170124 11448029 (Pubitemid 32477404)
5. Characterization of immune response of young pigs to porcine circovirus type 2 infection. RM Pogranichnyy KJ Yoon PA Harms SL Swenson JJ Zimmerman SD Sorden, Viral Immunol 2000 13 143 53 10.1089/vim.2000.13.143 10892995 (Pubitemid 30419193)
6. Immunisation against PCV2 structural protein by DNA vaccination of mice. S Kamstrup AM Barfoed TH Frimann AS Ladekjær-Mikkelsen A Bøtner, Vaccine 2004 22 1358 61 10.1016/j.vaccine.2004.01.032 15063557 (Pubitemid 38446911)
7. DNA vaccination of neonate piglets in the face of maternal immunity induces humoral memory and protection against a virulent pseudorabies virus challenge. L Fischer S Barzu C Andreoni N Buisson A Brun JC Audonnet, Vaccine 2003 21 15 1732 41 10.1016/S0264-410X(02)00736-3 12639497 (Pubitemid 36287603)
8. Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice. CA Siegrist C Barrios X Martinez C Brandt M Berney M Cordova,, et al. Eur J Immunol 1998 28 12 4138 48 10.1002/(SICI)1521-4141(199812)28:12<4138:: AID-IMMU41383.0.CO;2-L 9862350 (Pubitemid 28558644)
9. Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies. RD Weeratna CL Brazolot Millan MJ McCluskie CA Siegrist HL Davis, FEMS Immunol Med Microbiol 2001 30 3 241 47 10.1111/j.1574-695X.2001.tb01577.x 11335145 (Pubitemid 32373300)
10. Delivery systems for gene-based vaccines. TW Dubensky Jr MA Liu JB Ulmer, Mol Med 2000 6 9 723 32 11071268
11. Relative potency of cellular and humoral immune responses induced by DNA vaccination. GR Otten B Doe M Schaefer M Chen MJ Selby C Goldbeck,, et al. Intervirology 2000 43 227 32 10.1159/000053990 11251378 (Pubitemid 32225694)
12. Current progress of DNA vaccine studies in humans[J]. S Lu S Wang JM Grimes-Serrano, Expert Rev Vaccines 2008 7 2 175 91 10.1586/14760584.7.2.175 18324888 (Pubitemid 351357954)
13. Chemical adjuvants for plasmid DNA vaccines. JR Greenland NL Letvin, Vaccine 2007 25 3731 3741 10.1016/j.vaccine.2007.01.120 17350735 (Pubitemid 46613830)
14. DNA vaccines: developing new strategies to enhance immune responses. SA Abdulhaqq DB Weiner, Immunol Res 2008 42 219 232 10.1007/s12026-008-8076-3 19066740
15. Immunity by ubiquitylation: a reversible process of modification. YC Liu J Penninger M Karin, Nat Rev Immunol 2005 5 12 941 52 10.1038/nri1731 16322747 (Pubitemid 41746763)
16. The N-end rule: functions, mysteries, uses. A Varshavsky, Proc Natl Acad Sci USA 1996 93 22 12142 49 10.1073/pnas.93.22.12142 8901547 (Pubitemid 26367109)
17. The ubiquitin system. A Hershko A Ciechanover, Annu Rev Biochem 1998 67 425 79 10.1146/annurev.biochem.67.1.425 9759494 (Pubitemid 28411135)
18. The ubiquitin-proteasome pathway and pathogenesis of human diseases. AL Schwartz A Ciechanover, Annu Rev Med 1999 50 57 74 10.1146/annurev.med.50.1.57 10073263 (Pubitemid 29117052)
19. Proteolysis and class I major histocompatibility complex antigen presentation. IA York AL Goldberg XY Mo KL Rock, Immunol Rev 1999 172 1 49 66 10.1111/j.1600-065X.1999.tb01355.x 10631936 (Pubitemid 30000468)
20. DNA immunization:ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. F Rodriguez J Zhang JL Whitton, J Virol 1997 71 11 8497 503 9343207 (Pubitemid 27446431)
21. Targeting of HIV-1 Antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. TW Tobery RF Siliciano, J Exp Med 1997 185 5 909 20 10.1084/jem.185.5.909 9120397 (Pubitemid 27119875)
22. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes. Y Wu TJ Kipps, J Immunol 1997 159 12 6037 43 9550402 (Pubitemid 127471540)
23. DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity. G Delogu A Howard FM Collins SL Morris, Infect Immun 2000 68 6 3097 102 10.1128/IAI.68.6.3097-3102.2000 10816449 (Pubitemid 30340395)
24. Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens. TM Fu L Guan A Friedman JB Ulmer MA Liu JJ Donnelly, Vaccine 1998 16 18 1711 17 10.1016/S0264-410X(98)00134-0 9778746 (Pubitemid 28545100)
25. Preparation and characterization of monoclonal antibodies against Cap of PCV2. HZ Li F Fu YX Zhang X Li SP Song, Heilongjiang Animal Science and Veterinary Medicine 2010 3 120 22 (in Chinese)
26. Quantitation of porcine circovirus of type 2 using a SYBR Green I real-time PCR. HX Xu F Fu JH Lu X Li, Chinese Journal of Veterinary Medicine 2007 43 12 13 14 (in Chinese)
27. Prokaryotic expression of NLS deleted ORF2 capsid protein of porcine circovirus type 2. LJ Miao F Fu XW Wang WJ Chen JH Lu X Li, Chinese Journal of Preventive Veterinary Medicine 2008 30 5 384 87 (in Chinese)
28. Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B. SM Kang QZ Yao LZ Guo RW Compans, J Virol 2003 77 18 9823 30 10.1128/JVI.77.18.9823-9830.2003 12941891 (Pubitemid 37122063)
29. Generation and immunogenicity of a recombinant pseudorabies virus expressing cap protein of porcine circovirus type 2. YF Song ML Jin SL Zhang XJ Xu SB Xiao SB Cao,, et al. Vet Microbiol 2007 119 2/4 97 104 17005335
30. Immunogenicity of porcine circovirus type 2 capsid protein targeting to different subcellular compartments. HY Fan SB Xiao TZ Tong SP Wang LL Xie YB Jiang,, et al. Mol Immunol 2008 45 3 653 60 10.1016/j.molimm.2007.07.009 17709139
31. Systemic cytokine profiles of mice vaccinated with naked DNAs encoding six open reading frame antigens of porcine circovirus type 2 (PCV2). DJ An DS Song BK Park, Res Vet Sci 2008 85 3 503 09 10.1016/j.rvsc.2008.03.006 18456294
32. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. A Townsend J Bastin K Gould G Brownlee M Andrew B Coupar,, et al. J Exp Med 1988 168 4 1211 24 10.1084/jem.168.4.1211 2459295
33. An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. M Kozak, Nucleic Acids Res 1987 15 20 8125 48 10.1093/nar/15.20.8125 3313277
34. Antigen-specific CD8+ T cells induced by the ubiquitin fusion degradation pathway. I Takashi XF Duan H Hajime H Kunisuke, BBRC 2008 365 4 758 63 18029260
35. Functional diversity of helper T lymphocytes. AK Abbas KM Murphy A Sher, Nature 1996 383 787 93 10.1038/383787a0 8893001 (Pubitemid 26372655)
36. Heterogeneity of cytokine secretion patterns and functions of helper T cells. TR Mosmann RL Coffman, Adv Immunol 1989 46 111 47 2528896 (Pubitemid 19254750)
37. Correlation between the presence of neutralizing antibodies against porcine circovirus 2 (PCV2) and protection against replication of the virus and development of PCV2-associated disease. P Meerts G Misinzo D Lefebvre J Nielsen A Botner CS Kristensen,, et al. BMC Vet Res 2006 2 6
38. Detection of neutralizing antibodies in postweaning multisystemic wasting syndrome (PMWS)-affected and non-PMWS-affected pigs. M Fort A Olvera M Sibila J Segalés E Mateu, Vet micro 2007 125 3-4 244 55 10.1016/j.vetmic.2007.06. 004 (Pubitemid 47588667)